Display options
Cite
Gu C, Chen Y, Chen Y, et al. Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease. Front Aging Neurosci. 2021;13:768156doi: 10.3389/fnagi.2021.768156.
Gu, C., Chen, Y., Chen, Y., Liu, C. F., Zhu, Z., & Wang, M. (2021). Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease. Frontiers in aging neuroscience, 13768156. https://doi.org/10.3389/fnagi.2021.768156
Gu, Chao, et al. "Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease." Frontiers in aging neuroscience vol. 13 (2021): 768156. doi: https://doi.org/10.3389/fnagi.2021.768156
Gu C, Chen Y, Chen Y, Liu CF, Zhu Z, Wang M. Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease. Front Aging Neurosci. 2021 Nov 16;13:768156. doi: 10.3389/fnagi.2021.768156. eCollection 2021. PMID: 34867296; PMCID: PMC8635063.
Copy Download .nbib Format: NLM
Share it on

Front Aging Neurosci. 2021 Nov 16;13:768156. doi: 10.3389/fnagi.2021.768156. eCollection 2021.

Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease.

Frontiers in aging neuroscience

Chao Gu, Yajing Chen, Yan Chen, Chun-Feng Liu, Zengyan Zhu, Mei Wang

Affiliations

  1. Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
  2. Department of Child and Adolescent Healthcare, Children's Hospital of Soochow University, Suzhou, China.
  3. Department of Neurology, Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.

PMID: 34867296 PMCID: PMC8635063 DOI: 10.3389/fnagi.2021.768156

Abstract

Parkinson's disease (PD) is one of the prevalent neurodegenerative diseases associated with preferential loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and accumulation of α-synuclein in DA neurons. Even though the precise pathogenesis of PD is not clear, a large number of studies have shown that microglia-mediated neuroinflammation plays a vital role in the process of PD development. G protein-coupled receptors (GPCRs) are widely expressed in microglia and several of them act as regulators of microglial activation upon corresponding ligands stimulations. Upon α-synuclein insults, microglia would become excessively activated through some innate immune receptors. Presently, as lack of ideal drugs for treating PD, certain GPCR which is highly expressed in microglia of PD brain and mediates neuroinflammation effectively could be a prospective source for PD therapeutic intervention. Here, six kinds of GPCRs and two types of innate immune receptors were introduced, containing adenosine receptors, purinergic receptors, metabotropic glutamate receptors, adrenergic receptors, cannabinoid receptors, and melatonin receptors and their roles in neuroinflammation; we highlighted the relationship between these six GPCRs and microglial activation in PD. Based on the existing findings, we tried to expound the implication of microglial GPCRs-regulated neuroinflammation to the pathophysiology of PD and their potential to become a new expectation for clinical therapeutics.

Copyright © 2021 Gu, Chen, Chen, Liu, Zhu and Wang.

Keywords: G protein-coupled receptor (GPCR); Parkinson’s disease; dopaminergic (DA) neuronal loss; microglial activation; neuroinflammation

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Int J Mol Sci. 2015 Jul 27;16(8):16981-7004 - PubMed
  2. Neuroimage. 2014 May 15;92:83-9 - PubMed
  3. Cell. 2019 Jan 24;176(3):459-467.e13 - PubMed
  4. Annu Rev Pharmacol Toxicol. 2016;56:361-83 - PubMed
  5. CNS Neurol Disord Drug Targets. 2017;16(3):257-265 - PubMed
  6. Mol Neurodegener. 2016 Apr 16;11:28 - PubMed
  7. Curr Med Chem. 2012;19(8):1119-34 - PubMed
  8. Nat Commun. 2013;4:1562 - PubMed
  9. Mol Neurobiol. 2016 Mar;53(2):1181-1194 - PubMed
  10. J Neuroinflammation. 2018 Nov 19;15(1):322 - PubMed
  11. Brain. 2018 Feb 1;141(2):496-504 - PubMed
  12. Neurochem Int. 2016 Jan;92:25-34 - PubMed
  13. Neurosci Lett. 2006 Mar 20;396(1):1-6 - PubMed
  14. Front Cell Neurosci. 2019 Nov 08;13:476 - PubMed
  15. Mol Aspects Med. 2017 Jun;55:4-8 - PubMed
  16. J Neuroinflammation. 2019 Dec 12;16(1):263 - PubMed
  17. Transl Res. 2016 Mar;169:112-28 - PubMed
  18. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:200-8 - PubMed
  19. CNS Neurosci Ther. 2019 Sep;25(9):899-910 - PubMed
  20. Ann N Y Acad Sci. 2000;917:376-86 - PubMed
  21. Cell. 2010 Mar 19;140(6):918-34 - PubMed
  22. J Immunol. 2011 Apr 1;186(7):4443-54 - PubMed
  23. Prostaglandins Other Lipid Mediat. 2013 Jan;100-101:1-14 - PubMed
  24. Neuropharmacology. 2015 Oct;97:18-34 - PubMed
  25. Annu Rev Physiol. 2017 Feb 10;79:619-643 - PubMed
  26. Cell Signal. 2018 Jan;41:65-74 - PubMed
  27. Neurosci Bull. 2020 Nov;36(11):1299-1314 - PubMed
  28. Neurochem Res. 2017 May;42(5):1524-1532 - PubMed
  29. J Neurochem. 2019 Aug;150(3):282-295 - PubMed
  30. Neurochem Int. 2019 Jun;126:218-228 - PubMed
  31. Acta Neuropathol Commun. 2020 Sep 10;8(1):159 - PubMed
  32. J Neuroimmunol. 2019 Jul 15;332:37-48 - PubMed
  33. Aging Cell. 2021 Jun;20(6):e13375 - PubMed
  34. Nat Commun. 2020 Mar 13;11(1):1386 - PubMed
  35. Front Aging Neurosci. 2017 May 26;9:148 - PubMed
  36. Int J Mol Sci. 2020 May 31;21(11): - PubMed
  37. Aging Cell. 2019 Apr;18(2):e12902 - PubMed
  38. Exp Neurol. 2016 Sep;283(Pt A):204-12 - PubMed
  39. Cell. 2019 Jan 24;176(3):448-458.e12 - PubMed
  40. Biomed J. 2017 Oct;40(5):245-256 - PubMed
  41. Nat Rev Neurol. 2020 Jan;16(1):9-29 - PubMed
  42. Sleep. 2018 Jul 1;41(7): - PubMed
  43. EMBO Mol Med. 2018 Aug;10(8): - PubMed
  44. Neurobiol Aging. 2007 Aug;28(8):1239-47 - PubMed
  45. Int J Mol Sci. 2018 Mar 13;19(3): - PubMed
  46. Glia. 2020 Feb;68(2):328-344 - PubMed
  47. J Immunol. 2011 Dec 15;187(12):6508-17 - PubMed
  48. Nat Neurosci. 2009 Jul;12(7):872-8 - PubMed
  49. J Neurochem. 2012 Apr;121(2):228-38 - PubMed
  50. Brain Behav Immun. 2017 Mar;61:326-339 - PubMed
  51. J Anesth. 2017 Feb;31(1):25-35 - PubMed
  52. J Neurosci Res. 2018 Feb;96(2):253-264 - PubMed
  53. Inflammation. 2020 Apr;43(2):701-711 - PubMed
  54. Neuropharmacology. 2017 Mar 15;115:166-179 - PubMed
  55. Pharmacol Res. 2017 Mar;117:9-19 - PubMed
  56. Mol Psychiatry. 2017 Feb;22(2):280-286 - PubMed
  57. Cell. 2018 Jan 11;172(1-2):41-54.e19 - PubMed
  58. Int J Mol Sci. 2014 Dec 18;15(12):23672-704 - PubMed
  59. J Immunol Res. 2014;2014:103780 - PubMed
  60. J Med Chem. 2014 Apr 24;57(8):3161-85 - PubMed
  61. Pharmacol Rev. 2012 Jul;64(3):645-75 - PubMed
  62. Neurochem Res. 2019 Oct;44(10):2413-2422 - PubMed
  63. Mol Pharmacol. 1986 Mar;29(3):307-13 - PubMed
  64. Nat Rev Neurosci. 2007 Jan;8(1):57-69 - PubMed
  65. J Psychiatry Neurosci. 2014 Jan;39(1):6-21 - PubMed
  66. J Neurosci. 1997 Jul 15;17(14):5327-33 - PubMed
  67. Nature. 2020 Jul;583(7817):603-608 - PubMed
  68. Neurotherapeutics. 2018 Apr;15(2):459-469 - PubMed
  69. Front Cell Neurosci. 2018 Nov 05;12:400 - PubMed
  70. Eur Neuropsychopharmacol. 2013 Nov;23(11):1645-55 - PubMed
  71. Brain Res Bull. 2019 Mar;146:244-252 - PubMed
  72. Neurosci Lett. 2010 Aug 16;480(2):97-100 - PubMed
  73. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76 - PubMed
  74. Neurosci Lett. 1998 Feb 6;242(1):37-40 - PubMed
  75. J Neurochem. 2010 Oct;115(2):450-9 - PubMed
  76. Neurochem Res. 2014 Nov;39(11):2240-50 - PubMed
  77. Cell. 2015 Jan 15;160(1-2):62-73 - PubMed
  78. J Neurochem. 2016 Dec;139(6):1019-1055 - PubMed
  79. J Neuroimmunol. 2019 Jul 15;332:16-30 - PubMed
  80. Glia. 2009 Nov 15;57(15):1600-9 - PubMed
  81. Glia. 2015 Feb;63(2):216-28 - PubMed
  82. Br J Pharmacol. 2020 Jan;177(2):282-297 - PubMed
  83. Nature. 1986 May 1-7;321(6065):75-9 - PubMed
  84. Cell Rep. 2017 May 9;19(6):1151-1164 - PubMed
  85. Mol Cell Biol. 2013 Nov;33(21):4282-93 - PubMed
  86. Glia. 2013 Dec;61(12):2023-37 - PubMed
  87. Glia. 2014 Jan;62(1):122-32 - PubMed
  88. Neural Regen Res. 2021 Dec;16(12):2505-2511 - PubMed
  89. Med Sci Monit. 2010 Feb;16(2):BR61-7 - PubMed
  90. Glia. 2013 Mar;61(3):349-60 - PubMed
  91. Br J Pharmacol. 2006 Jun;148(3):314-25 - PubMed
  92. Curr Med Chem. 2010;17(14):1411-29 - PubMed
  93. Synapse. 2017 Aug;71(8): - PubMed
  94. Nature. 2016 Nov 24;539(7630):555-559 - PubMed
  95. Cell Mol Neurobiol. 2020 Jan;40(1):167-177 - PubMed
  96. Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7997-E8006 - PubMed
  97. Neurotox Res. 2013 Apr;23(3):267-300 - PubMed
  98. J Immunol. 2012 Jan 1;188(1):445-53 - PubMed
  99. Mov Disord. 2017 May;32(5):682-692 - PubMed
  100. Neural Regen Res. 2018 Aug;13(8):1332-1337 - PubMed
  101. J Neurochem. 2013 May;125(3):362-72 - PubMed
  102. Neurology. 1988 Aug;38(8):1285-91 - PubMed
  103. J Neuroinflammation. 2017 Feb 20;14(1):38 - PubMed
  104. Nat Rev Immunol. 2018 Apr;18(4):225-242 - PubMed
  105. Annu Rev Immunol. 2017 Apr 26;35:441-468 - PubMed
  106. Neuropharmacology. 2016 May;104:50-61 - PubMed
  107. Exp Neurol. 2015 Jul;269:133-41 - PubMed
  108. Usp Fiziol Nauk. 2016 Apr-Jun;47(2):98-112 - PubMed
  109. Front Mol Neurosci. 2020 Aug 07;13:111 - PubMed
  110. J Neurochem. 2014 Apr;129(1):4-20 - PubMed
  111. Int J Mol Sci. 2020 Dec 22;22(1): - PubMed
  112. Cell Death Dis. 2019 Feb 18;10(3):165 - PubMed
  113. J Neurochem. 1999 Apr;72(4):1671-80 - PubMed
  114. Biochem J. 2015 Nov 1;471(3):323-33 - PubMed
  115. J Neurochem. 2003 Aug;86(4):1051-4 - PubMed
  116. Molecules. 2021 Feb 23;26(4): - PubMed
  117. Cells. 2020 Jul 17;9(7): - PubMed
  118. Nat Neurosci. 2005 Jun;8(6):752-8 - PubMed
  119. Brain. 2019 Mar 1;142(3):700-718 - PubMed
  120. Mol Pharmacol. 2003 Jun;63(6):1256-72 - PubMed
  121. Cancer Res. 2006 Sep 1;66(17):8550-7 - PubMed
  122. CNS Drugs. 2007;21(12):995-1018 - PubMed
  123. Nat Rev Immunol. 2013 Jun;13(6):397-411 - PubMed
  124. J Neurosci. 2011 Oct 12;31(41):14496-507 - PubMed
  125. Cytokine. 2015 Aug;74(2):181-9 - PubMed
  126. Free Radic Biol Med. 2019 Feb 1;131:345-355 - PubMed
  127. J Neuroimmunol. 2018 Apr 15;317:37-44 - PubMed
  128. Pharmacol Res. 2017 Jan;115:179-191 - PubMed
  129. Nat Rev Neurosci. 2018 Oct;19(10):610-621 - PubMed
  130. Sci Rep. 2013;3:1393 - PubMed
  131. J Pineal Res. 2016 Oct;61(3):253-78 - PubMed
  132. Pharmacol Rep. 2018 Aug;70(4):661-667 - PubMed
  133. Int J Mol Sci. 2020 Aug 20;21(17): - PubMed
  134. Curr Opin Pharmacol. 2017 Feb;32:91-95 - PubMed
  135. Pharmacol Res. 2016 Sep;111:1-16 - PubMed
  136. Neurobiol Dis. 2014 Jul;67:191-202 - PubMed
  137. Exp Neurol. 2014 Aug;258:5-16 - PubMed
  138. Protein Sci. 1993 Aug;2(8):1198-209 - PubMed
  139. Biochem Pharmacol. 2016 Mar 1;103:1-16 - PubMed
  140. J Neural Transm Suppl. 2006;(70):373-81 - PubMed
  141. Front Pharmacol. 2017 Nov 09;8:812 - PubMed
  142. Cells. 2020 Feb 23;9(2): - PubMed
  143. Autoimmun Rev. 2016 Oct;15(10):1005-11 - PubMed
  144. Nat Neurosci. 2016 Jul 26;19(8):987-91 - PubMed
  145. Nat Neurosci. 2006 Dec;9(12):1512-9 - PubMed
  146. Brain Behav Immun. 2018 Jul;71:93-107 - PubMed
  147. J Neuroinflammation. 2021 Jan 18;18(1):23 - PubMed
  148. Prog Neurobiol. 2011 Mar;93(3):350-84 - PubMed
  149. Cells. 2020 Jul 01;9(7): - PubMed
  150. Cell. 2019 Oct 3;179(2):292-311 - PubMed
  151. J Exp Med. 2017 May 1;214(5):1351-1370 - PubMed

Publication Types